Metastasis-directed therapy in castrationrefractory prostate cancer (MEDCARE): A non-randomized phase 2 trial

: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease.